174.08
-1.05%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Palvella Therapeutics
From its filings with the US Securities and Exchange Commission
Palvella Therapeutics is based in Wayne, Pennsylvania and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker PVLA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2023, it reported revenue of $42.8m.
On December 13, 2024, we completed the previously announced business combination with Legacy Palvella in accordance with the terms of the Merger Agreement, pursuant to which, among other matters, Merger Sub merged with and into Legacy Palvella, with Legacy Palvella surviving as our wholly owned subsidiary (such business combination, the Merger). In connection with the completion of the Merger, we changed our name from “Pieris Pharmaceuticals, Inc.” to “Palvella Therapeutics, Inc.,” and our business became primarily the business conducted by Legacy Palvella. We are now a clinical-stage biopharmaceutical company focused on developing and, if approved, commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies.
We are a clinical-stage biopharmaceutical company whose vision is to become the leading rare disease biopharmaceutical company focused on developing and, if approved, commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. We envision a future treatment paradigm in which individuals suffering from serious, rare skin diseases and vascular malformations, and the physicians treating those diseases, have significantly improved treatment options which address the underlying causes of those diseases. We intend to leverage our versatile QTORIN platform to minimize the challenges and timelines typically associated with generating novel topical product candidates.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Dec 2014
- Employees
- 29
- Website
- pieris.com ↗
- Head office
- 353 W. LANCASTER AVENUE, WAYNE, PA, 19087
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. George JenkinsIndependent Chairman of the Board$318,142
- Mr. Wesley KaupinenPresident, Chief Executive Officer, Founder, Director, since 2024$5.4m
- Mr. Matthew KorenbergChief Financial Officer
- Ms. Kathleen GoinChief Operating Officer$1.1m
- Dr. Jeffrey MartiniChief Scientific Officer$1.9m
- Dr. David OsborneChief Innovation Officer
- Mr. Todd DavisIndependent Director$318,142
- Ms. Elaine HeronIndependent Director$231,844
- Mr. Christopher KiritsyIndependent Director$301,235
- Mr. Tadd WesselIndependent Director$231,844
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 56
- Environment
- 58
- Social
- 77
- Governance
- 33
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pieris Pharmaceuticals has 114 full-time employees in Boston, US, focusing on biotechnology innovation.
- The company's Anticalin-based drugs target hepcidin, IL-4RA, and tumor micro-environments for therapeutic applications.
- PRS-080, PRS-060, and PRS-343 are key drug candidates in the clinical-stage pipeline.
Weaknesses
- Pieris Pharmaceuticals has only 29 employees, indicating limited workforce capacity.
- The company's IPO in 2014 suggests a relatively short operational history.
- The firm's pipeline focuses on three drug candidates, which may limit diversification.
Opportunities
- The US market offers significant growth potential for biotechnology companies like Pieris.
- Expanding into immuno-oncology and asthma treatments presents new market segments.
- The development of half-life-optimized Anticalin proteins could attract new investors.
Threats
- Competition in the biotechnology sector is intense, with many established players.
- Regulatory challenges may delay the approval of new drug candidates.
- The high cost of clinical trials could strain financial resources.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.